Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NRXP
SellHot AirNRx Pharmaceuticals, Inc. · Healthcare · United States · $154M · Avg Vol: $3M/d
COMPANY DESCRIPTION
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders and life-threatening inflammatory diseases. The company's lead pipeline candidates target suicidal depression, bipolar depression, and acute respiratory failure. NRx leverages proprietary scientific discoveries to address high-barrier medical niches with significant unmet clinical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1.2M | — | 3.4M | 6.4M | 106.4M | 832.0% |
| EPS | -0.95 | -0.78 | -0.80 | -1.34 | — | -0.51 | -0.36 | 0.50 | — |
| Shares | 42.8M | 42.8M | 42.8M | 31.7M | -25.9% | — | — | — | — |
| Debt | 10.5M | 9.2M | 6.6M | 0.6M | -60.9% | 0.8M | — | — | — |
| Equity | 7.4M | -11.7M | -23.2M | -15.9M | — | — | — | — | — |
| Op CF | -39.8M | -21.7M | -10.6M | -14.1M | — | -19.8M | — | — | — |
| Inv CF | -10.0K | -3.0K | 0 | -2.8M | — | — | — | — | — |
| Fin CF | 32.2M | 6.2M | 7.5M | 23.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NRXP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NRXP | NRx Pharmaceuticals, Inc.(you) | $154M | 24 | Sell |
| OKUR | OnKure Therapeutics, Inc. | $153M | 27 | Sell |
| BDTX | Black Diamond Therapeutics, Inc. | $128M | 23 | Sell |
| CDXS | Codexis, Inc. | $174M | 21 | Sell |
| EQ | Equillium, Inc. | $152M | 29 | Sell |
| NKTX | Nkarta, Inc. | $198M | 25 | Sell |
| VTVT | vTv Therapeutics Inc. | $128M | 19 | Strong Sell |
| BMEA | Biomea Fusion, Inc. | $125M | 18 | Strong Sell |
| OTLK | Outlook Therapeutics, Inc. | $156M | 14 | Strong Sell |
| TNYA | Tenaya Therapeutics, Inc. | $155M | 14 | Strong Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%